33 results on '"Mendoza, C."'
Search Results
2. POS0745 RISK FACTORS FOR HOSPITALIZATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A LATIN COHORT
3. FRI0050 EFFICACY OF ATORVASTATIN VERSUS COLCHICINE IN DECREASING BIOMARKERS OF MYOCARDIAL DAMAGE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS
4. OP0291 TOFACITINIB FOR THE TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: RESULTS OF A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED WITHDRAWAL STUDY
5. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
6. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor α agents
7. AB1025 Glycemia and Systemic Blood Pressure in Patients Who Receive Corticosteroid Pulse Therapy
8. RISK FACTORS FOR POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH RHEUMATIC DISEASES.
9. AB1138 Hospitalizations and Mortality in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Impact of Comorbidities
10. AB0592 Role of Immunoglobulin and Complement Deposits in Activity, Chronicity and Classes of Lupus Nephritis
11. AB1074 Hospitalizations and Mortality in Mexican Patients with Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA): Table 1.
12. FRI0529 Occupational Status of Patients with Childhood Onset Rheumatologic Diseases: Table 1.
13. AB0891 Long-Term Cumulative Organ Damage Assessment in A Cohort of Patients with Juvenile Dermatomyositis: Table 1
14. FRI0422 Analysis of Lymphocyte Subpopulations and NK Cell Receptors Expression in Patients with Systemic Lupus Erythematosus (SLE) Infected with Papillomavirus (HPV)
15. FRI0421 Immune Effects of Human Papilloma Virus (HPV) Immunization in Patients with Systemic Lupus Erythematosus (SLE)
16. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor (alpha) agents
17. THU0130 Assessment of transaminasitis with daily methotrexate therapy in patients with inflammatory rheumatic diseases. A long-term follow-up cohort study
18. AB0687 Factors associated with common warts in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
19. AB0518 High percentage of dermoconversion in patients with rheumatoid arthritis under biological therapy
20. FRI0286 Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. a subgroup analysis.
21. THU0189 Invasive fungal infections in patients with systemic lupus erythematosus
22. OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study
23. FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the planetas study
24. Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor agents
25. Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis'.
26. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.
27. Statins in systemic lupus erythematosus.
28. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
29. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
30. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.
31. Are steroids required for induction therapy and relapses in lupus nephritis?
32. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.
33. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.